Receptor targets
Tirzepatide is defined as a dual incretin receptor agonist, engaging both the GIP receptor and the GLP-1 receptor. These are the two incretin receptors, class B G-protein-coupled receptors that mediate glucose-dependent insulin signaling, and tirzepatide is engineered to activate both from a single molecule.
Its molecular design is based on the native GIP peptide sequence, modified so that it acts as an agonist at both incretin receptors rather than at GIP alone.
- GIP receptor (glucose-dependent insulinotropic polypeptide).
- GLP-1 receptor (glucagon-like peptide-1).
- Single molecule engineered for dual incretin agonism.
- Backbone derived from the native GIP sequence.
Mechanism of action
As a class B GPCR agonist, tirzepatide binds the GIP and GLP-1 receptors and drives Gs-coupled signaling, canonically increasing intracellular cyclic AMP and downstream signaling in receptor-expressing cells. Both receptors sit on the incretin axis studied in relation to glucose-dependent insulin signaling, and the interest in a dual agonist is in the combined effect of engaging both simultaneously from one molecule.
The relative potency and signaling balance between the GIP and GLP-1 arms is itself a subject of characterization in the research literature, which studies how a single co-agonist compares to activating either receptor alone.
Molecular design and half-life extension
Tirzepatide is a synthetic peptide incorporating non-native amino acids that stabilize its structure and a C20 fatty-diacid (lipidation) moiety that promotes reversible binding to serum albumin. Albumin binding is the design strategy associated in the literature with its extended circulating half-life, allowing the dual-receptor pharmacology to be studied over a prolonged window.
These engineered features — modified residues plus the acyl chain — are what let a single synthetic molecule act at both incretin receptors while resisting rapid enzymatic degradation.
- Peptide backbone derived from native GIP, with non-native residues.
- C20 fatty-diacid (lipidation) moiety for albumin binding.
- Albumin binding associated with extended half-life in the literature.
- Modifications confer resistance to rapid enzymatic clearance.
Dual vs triple agonism
Tirzepatide is frequently discussed alongside retatrutide, a triple incretin receptor agonist. The distinction is the number of receptor targets: tirzepatide activates two receptors (GIP and GLP-1), while retatrutide activates a third, the glucagon receptor.
This makes tirzepatide the reference dual agonist against which triagonist pharmacology is compared. The comparison is developed further on the dedicated comparison page.
- Tirzepatide: dual agonist — GIP + GLP-1 receptors.
- Retatrutide: triple agonist — adds the glucagon receptor.
- Tirzepatide serves as the dual-agonist comparator in the literature.
What the literature investigates
Research on tirzepatide characterizes its binding and activation at the GIP and GLP-1 receptors, its signaling balance between the two arms, its pharmacokinetics, and its metabolic signaling effects in cellular and preclinical models. As a reference material it is widely used as a comparator for both single agonists and newer multi-agonists.
This is laboratory and preclinical work. Kairo Labs supplies tirzepatide as a research reference compound for research use only; it is not for human or animal consumption, and nothing here describes therapeutic use or dosing.
Verification and quality
Tirzepatide is a large modified synthetic peptide, so lot-level identity and purity confirmation is essential. Each lot should carry a Certificate of Analysis with HPLC purity and its chromatogram, mass-spec identity comparing observed versus theoretical mass, and net peptide content. Kairo Labs verifies to the lot — every batch is tested and its data retrievable.
The COA guide explains how to interpret those results, and the handling guides cover reconstitution, storage, and stability for peptides of this class.